Quality Of Life While Receiving Faslodex

Quality Of Life And Symptoms In Postmenopausal Women With Hormone Receptor Positive Disseminated Breast Cancer While Receiving Faslodex.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00643513

Enrollment

120

Registered

2008-03-26

Start date

2007-06-30

Completion date

2009-01-31

Last updated

2009-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

QUALITY OF LIFE, POSTMENOPAUSAL WOMEN, HORMONE RECEPTOR POSITIVE DISSEMINATED BREAST CANCER, FASLODEX

Brief summary

To study QoL related response, symptom spectrum and severity in disseminated breast cancer patients receiving Faslodex hormonal therapy.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histologic and/or cytological proven breast cancer. * Patients with metastases of breast cancer ± postmenopausal primary tumor ≥12 months. * Positive oestrogen receptors (ER+), positive progesterone receptors (PgR+) or unknown hormonal receptors (if duration between surgery and metastasis occurring is not less 2 years) which are indirect confirmation of hormone sensitive tumor. * ECOG performance status of ≤ 2 * Patient willingness to take part in the programm * Life expectancy of more than 6 months. * Patient ability to complete a questionnaire.

Exclusion criteria

* Contraindications for Faslodex therapy * Other anticancer therapy (chemotherapy, hormonal therapy with other drugs, radiotherapy), except for radiotherapy of sites which are not only measurable or evaluable manifestation of disease.

Design outcomes

Primary

Measure	Time frame
To study QoL related response, symptom spectrum and severity in disseminated breast cancer patients receiving Faslodex hormonal therapy.	—

Countries

Russia

Outcome results